{
    "nctId": "NCT06152471",
    "briefTitle": "Effect of Salovum\u2122 and SPC-Flakes\u2122 on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer",
    "officialTitle": "A Randomized Double-blind Placebo Controlled Phase 3 Trial on the Effect of Salovum\u2122 and SPC-Flakes\u2122 on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer - the ASF-BC Study",
    "overallStatus": "RECRUITING",
    "conditions": "Early-stage Breast Cancer, Diarrhea, Adverse Drug Event",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Occurrence of Abemaciclib induced diarrhea - STIDAT",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years.\n* Histologically confirmed diagnosis of luminal breast cancer.\n* No clinical evidence of metastatic disease.\n* Planned to start abemaciclib in adjuvant setting (according to current national guidelines).\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Contraindications to the investigational product, e g known or suspected hypersensitivity to the investigational products or expected inability to their use in accordance with the protocol.\n* Lack of suitability for participation in the study, e g expected difficulties to follow the protocol procedures, as judged by the investigator.\n* Prior exposure to abemaciclib.\n* Prior exposure to Salovum or SPC-flakes.\n* Past or present history of inflammatory bowel disease.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}